NCT04692181View on ClinicalTrials.gov

SYN-004 Safety and Tolerability in Allo-HCT Subjects

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 15, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Acute Graft-Versus-Host Reaction Following Bone Marrow TransplantPrevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics
Interventions
BIOLOGICAL

SYN-004, Ribaxamase or Placebo

SYN-004 is an oral formulation of a recombinant class-A beta-lactamase that hydrolyzes the beta-lactam ring of susceptible antibiotics that are excreted into the intestines

Trial Locations (1)

63110

Washington University, St Louis

All Listed Sponsors
collaborator

Washington University School of Medicine

OTHER

lead

Theriva Biologics, Inc.

INDUSTRY

NCT04692181 - SYN-004 Safety and Tolerability in Allo-HCT Subjects | Biotech Hunter | Biotech Hunter